Business
Aura Biosciences is developing bel-sar, its only product candidate to date, with an initial focus on ocular and urologic oncology.
Aura Biosciences remained pre-revenue, losses and cash burn worsened, equity fell, and insider activity was sales-only.
The read at a glance✓ Audited against SEC data
- Business mix — Bel-sar oncology candidateNote
- Revenue — No revenue taggedNote
- Losses — Net loss widened to $106.2MWatch
- Cash — FCF fell to -$85.2MWatch
- Balance sheet — Equity fell 9.9%Watch
- Insiders — 0 buys / 13 sellsWatch
- Accounting — Forensic screen unavailableNote
Leadership changes
From Aura Biosciences, Inc.'s own filings, the day they're filed.
- Jeremy Bender · director · appointmenteff. 2026-07-07
- Natalie Holles · Chief Executive Officer · appointmenteff. 2026-04-30
- Elisabet de · Chief Executive Officer · departureeff. 2026-04-30
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-07-08
- DEF 14A · Annual proxy (pay & governance)2026-06-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aura Biosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.